<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2021-19-164-169</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-6545</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕВМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RHEUMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Гендерные особенности течения подагры и различия в ответе на прием ингибиторов ксантиоксидазы</article-title><trans-title-group xml:lang="en"><trans-title>Gender characteristics of gout and differences in response to taking xanthioxidase inhibitors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8040-3704</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цурко</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsurko</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цурко Владимир Викторович, профессор кафедры факультетской терапии лечебного факультета; д.м.н., профессор кафедры общей врачебной практики института последипломного образования</p><p>117997, Россия, Москва, ул. Островитянова, д. 1</p><p>119991, Россия, Москва, ул. Трубецкая, д. 8</p></bio><bio xml:lang="en"><p>Vladimir V. Tsurko, Professor of the Department of Faculty Therapy of the Medical Faculty; Dr. Sci. (Med.), Professor of the Department of General Medical Practice of the Institute of Postgraduate Education</p><p>1, Ostrovityanov St., Moscow, 117997, Russia</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991, Russia</p></bio><email xlink:type="simple">vvtsurko@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3757-058X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Громова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gromova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Громова Маргарита Александровна, к.м.н., ассистент кафедры факультетской терапии лечебного факультета</p><p>117997, Россия, Москва, ул. Островитянова, д. 1</p></bio><bio xml:lang="en"><p>Margarita A. Gromova, Cand. Sci. (Med.), Assistant of The Department of Faculty Therapy of the Medical Faculty</p><p>1, Ostrovityanov St., Moscow, 117997, Russia</p></bio><email xlink:type="simple">margarita-gromov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова; Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University; Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2021</year></pub-date><volume>0</volume><issue>19</issue><fpage>164</fpage><lpage>169</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Цурко В.В., Громова М.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Цурко В.В., Громова М.А.</copyright-holder><copyright-holder xml:lang="en">Tsurko V.V., Gromova M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/6545">https://www.med-sovet.pro/jour/article/view/6545</self-uri><abstract><sec><title>Введение</title><p>Введение. На сегодняшний день нет единого мнения относительно гендерных особенностей течения подагры. Существует мало данных о возможной разнице между мужчинами и женщинами в ответе на терапию, снижающую уровень мочевой кислоты.</p></sec><sec><title>Цель</title><p>Цель. Сравнить клинические характеристики течения подагры и оценить различия в ответе на уратснижающую терапию (УСТ) аллопуринолом и фебуксостатом у мужчин и женщин.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Ретроспективное когортное исследование включало 279 мужчин и 83 женщины с диагнозом подагры (ACR/EULAR, 2015 г.). Проведен сравнительный анализ клинических характеристик подагры, а также ответов на прием ингибиторов ксантиоксидазы (КО) у представителей разных полов. Сравнивались гендерные особенности получения положительного ответа на УСТ, определяемого как достижение целевого уровня сывороточной мочевой кислоты (сМК) &lt; 360 мкмоль/л в течение 6 месяцев лечения, при приеме аллопуринола и фебуксостата.</p></sec><sec><title>Результаты</title><p>Результаты. По возрасту, в котором состоялся дебют подагры, женщины были старше мужчин, длительность заболевания у них – короче. У мужчин выявлена меньшая продолжительность первого приступа артрита. Хронический артрит был констатирован у 56% мужчин и 35% женщин (p &lt; 0,05). В процесс вовлекались суставы как нижних, так и верхних конечностей. Однако чаще суставы нижних конечностей поражались у мужчин, а верхних конечностей – у женщин. Тофусы были выявлены у 35% больных, из них мужчины составляли 30,3%, женщины – 4,7% (p &lt; 0,05). Аллопуринол был назначен 216 мужчинам и 54 женщинам, фебуксостат – 63 мужчинам и 29 женщинам. Через шесть месяцев доля женщин, достигших целевого показателя сМК, составила 57,5% и 65,8%, доля мужчин – 60,4% и 76,2% для аллопуринола и фебуксостата соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. Клинические проявления подагры у мужчин и женщин различаются. Благодаря выраженному повышению уровня мочевой кислоты у мужчин развивается более тяжелое поражение суставов за счет тенденции к хронизации. Однако исследование не выявило гендерных различий в ответе на прием ингибиторов КО, что говорит об отсутствии необходимости выбора терапии в зависимости от пола больного.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. To date, there is no consensus regarding the gender characteristics of the course of gout. There is little data on the possible difference between men and women in response to uric acid-lowering therapy.</p></sec><sec><title>Aim</title><p>Aim. To compare the clinical characteristics of the course of gout and evaluate the differences in response to urate-lowering therapy (ULT) with allopurinol and febuxostat in men and women.</p></sec><sec><title>Material and methods</title><p>Material and methods. The retrospective cohort study included 279 men and 83 women diagnosed with gout (ACR/EULAR, 2015). The comparative analysis of the clinical characteristics of gout, as well as responses to the intake of xanthioxidase (XO) inhibitors in representatives of different sexes, was carried out. We compared the gender characteristics of obtaining a positive response to ULT, defined as achieving a target serum uric acid (sUA) level of &lt; 360 μmol / l within 6 months of treatment, while taking allopurinol and febuxostat.</p></sec><sec><title>Results</title><p>Results. By the age at which the onset of gout took place, women were older than men, the duration of the disease in them was shorter. Men showed a shorter duration of the first attack of arthritis. Chronic arthritis was diagnosed in 56% of men and 35% of women (p &lt; 0.05). The process involved the joints of both the lower and upper extremities. However, more often the joints of the lower extremities were affected in men, and in the upper extremities in women. Tophus were detected in 35% of patients, of whom 30.3% were men, 4.7% were women (p &lt; 0.05). Allopurinol was prescribed to 216 men and 54 women, and febuxostat was prescribed to 63 men and 29 women. After six months, the proportion of women who achieved the target sUA was 57.5% and 65.8%, the proportion of men – 60.4% and 76.2% for allopurinol and febuxostat, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. The clinical manifestations of gout in men and women differ. Due to the pronounced increase in the level of uric acid, men develop more severe joint damage due to the tendency to chronicity. However, the study did not reveal gender differences in the response to XO inhibitors, which indicates that there is no need to choose therapy depending on the patient’s gender.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>подагра</kwd><kwd>мужчины</kwd><kwd>женщины</kwd><kwd>артрит</kwd><kwd>тофусы</kwd><kwd>уратснижающая терапия</kwd><kwd>аллопуринол</kwd><kwd>фебуксостат</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gout</kwd><kwd>men</kwd><kwd>women</kwd><kwd>arthritis</kwd><kwd>tophus</kwd><kwd>urate-lowering therapy</kwd><kwd>allopurinol</kwd><kwd>febuxostat</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo C.F., Grainge M.J., Zhang W., Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–662. https://doi.org/10.1038/nrrheum.2015.91.</mixed-citation><mixed-citation xml:lang="en">Kuo C.F., Grainge M.J., Zhang W., Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–662. https://doi.org/10.1038/nrrheum.2015.91.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bhole V., de Vera M., Rahman M.M., Krishnan E., Choi H. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum. 2010;62(4):1069–1076. https://doi.org/10.1002/art.27338.</mixed-citation><mixed-citation xml:lang="en">Bhole V., de Vera M., Rahman M.M., Krishnan E., Choi H. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum. 2010;62(4):1069–1076. https://doi.org/10.1002/art.27338.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dirken-Heukensfeldt K.J., Teunissen T.A., van de Lisdonk H., LagroJanssen A.L. “Clinical features of women with gout arthritis.” A systematic review. Clinic Rheum. 2010;29(6):575–582. https://doi.org/10.1007/s10067-009-1362-1.</mixed-citation><mixed-citation xml:lang="en">Dirken-Heukensfeldt K.J., Teunissen T.A., van de Lisdonk H., LagroJanssen A.L. “Clinical features of women with gout arthritis.” A systematic review. Clinic Rheum. 2010;29(6):575–582. https://doi.org/10.1007/s10067-009-1362-1.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Harrold L.R., Etzel C.J., Gibofsky A., Kremer J.M., Pillinger M.H., Saag K.G. et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18(1):108. https://doi.org/10.1186/s12891-017-1465-9.</mixed-citation><mixed-citation xml:lang="en">Harrold L.R., Etzel C.J., Gibofsky A., Kremer J.M., Pillinger M.H., Saag K.G. et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18(1):108. https://doi.org/10.1186/s12891-017-1465-9.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Harrold L.R., Yood R.A., Mikuls T.R., Andrade S.E., Davis J., Fuller J. et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–1372. https://doi.org/10.1136/ard.2006.051649.</mixed-citation><mixed-citation xml:lang="en">Harrold L.R., Yood R.A., Mikuls T.R., Andrade S.E., Davis J., Fuller J. et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–1372. https://doi.org/10.1136/ard.2006.051649.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев М.С., Чикаленкова Н.А., Барскова В.Г. Клинические особенности подагры у женщин: результаты сравнительного исследования. Научнопрактическая ревматология. 2014;52(2):178–182. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/1922.</mixed-citation><mixed-citation xml:lang="en">Eliseev M.S., Chikalenkova N.A., Barskova V.G. Clinical features of gout in women: the results of a comparative study. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):178–182. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/1922.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chohan S., Becker M.A., MacDonald P. A., Chefo S., Jackson R.L. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012;64(2):256–261. https://doi.org/10.1002/acr.20680.</mixed-citation><mixed-citation xml:lang="en">Chohan S., Becker M.A., MacDonald P. A., Chefo S., Jackson R.L. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012;64(2):256–261. https://doi.org/10.1002/acr.20680.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Institute of Medicine (US) Committee on Understanding the Biology of Sex and Gender Differences, Wizemann T.M., Pardue M.L. (eds.). Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington (DC): National Academies Press (US); 2001, pp. 6-9. https://doi.org/10.17226/10028.</mixed-citation><mixed-citation xml:lang="en">Institute of Medicine (US) Committee on Understanding the Biology of Sex and Gender Differences, Wizemann T.M., Pardue M.L. (eds.). Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington (DC): National Academies Press (US); 2001, pp. 6-9. https://doi.org/10.17226/10028.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Liu K.A., Mager N.A. Women’s involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016;14(1):708. Available at: https://ncbi.nlm.nih.gov/pmc/articles/PMC4800017.</mixed-citation><mixed-citation xml:lang="en">Liu K.A., Mager N.A. Women’s involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016;14(1):708. Available at: https://ncbi.nlm.nih.gov/pmc/articles/PMC4800017.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Puig J.G., Michan A.D., Jimenez M.L., Perez de Ayala C., Mateos F.A., Capitan C.F. et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. 1991;151(4):726–732. https://doi.org/10.1001/archinte.1991.00400040074016.</mixed-citation><mixed-citation xml:lang="en">Puig J.G., Michan A.D., Jimenez M.L., Perez de Ayala C., Mateos F.A., Capitan C.F. et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. 1991;151(4):726–732. https://doi.org/10.1001/archinte.1991.00400040074016.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Park Y.B., Park Y.S., Song J., Lee W.K., Suh C.H., Lee S.K. Clinical manifestations of Korean female gouty patients. Clin Rheumatol. 2000;19(2):142–146. https://doi.org/10.1007/s100670050033.</mixed-citation><mixed-citation xml:lang="en">Park Y.B., Park Y.S., Song J., Lee W.K., Suh C.H., Lee S.K. Clinical manifestations of Korean female gouty patients. Clin Rheumatol. 2000;19(2):142–146. https://doi.org/10.1007/s100670050033.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Walker V., Stansbridge E.M., Griffin D.G. Demography and biochemistry of 2800 patients from a renal stones clinic. Ann Clin Biochem. 2013;50(2):127–139. https://doi.org/10.1258/acb.2012.012122.</mixed-citation><mixed-citation xml:lang="en">Walker V., Stansbridge E.M., Griffin D.G. Demography and biochemistry of 2800 patients from a renal stones clinic. Ann Clin Biochem. 2013;50(2):127–139. https://doi.org/10.1258/acb.2012.012122.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Neogi T., Jansen T.L., Dalbeth N., Fransen J., Schumacher H.R., Berendsen D. et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–1798. https://doi.org/10.1136/annrheumdis-2015-208237.</mixed-citation><mixed-citation xml:lang="en">Neogi T., Jansen T.L., Dalbeth N., Fransen J., Schumacher H.R., Berendsen D. et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–1798. https://doi.org/10.1136/annrheumdis-2015-208237.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes:The Task Force for the diagnosis and management of chroni coronary syndromes of the European Society of Cardiology (ESC). European Heart J. 2020;41(3)407-477. https://doi.org/10.1093/eurheartj/ehz425.</mixed-citation><mixed-citation xml:lang="en">Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes:The Task Force for the diagnosis and management of chroni coronary syndromes of the European Society of Cardiology (ESC). European Heart J. 2020;41(3)407-477. https://doi.org/10.1093/eurheartj/ehz425.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Roglic G., Norris S.L. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: Synopsis of the World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med. 2018;169:394. https://doi.org/10.7326/M18-1149.</mixed-citation><mixed-citation xml:lang="en">Roglic G., Norris S.L. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: Synopsis of the World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med. 2018;169:394. https://doi.org/10.7326/M18-1149.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Humphrey L.L., Kansagara D., Qaseem A. World Health Organization guidelines on medicines for diabetes treatment intensification: Commentary from the American College of Physicians high value care committee. Ann Intern Med. 2018;169:398. https://doi.org/10.7326/M18-1148.</mixed-citation><mixed-citation xml:lang="en">Humphrey L.L., Kansagara D., Qaseem A. World Health Organization guidelines on medicines for diabetes treatment intensification: Commentary from the American College of Physicians high value care committee. Ann Intern Med. 2018;169:398. https://doi.org/10.7326/M18-1148.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kopple J.D. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001;37(1):S66-S70. https://doi.org/10.1053/ajkd.2001.20748.</mixed-citation><mixed-citation xml:lang="en">Kopple J.D. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001;37(1):S66-S70. https://doi.org/10.1053/ajkd.2001.20748.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические Практические Рекомендации KDIGO 2012 по Диагностике и Лечению Хронической Болезни Почек. Нефрология и диализ. 2017.19(1):10–225. https://doi.org/10.28996/1680-4422-2017-1-22-206.</mixed-citation><mixed-citation xml:lang="en">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Nefrologiya i dializ = Nephrology and Dialysis. 2017.19(1):10–225. (In Russ.) https://doi.org/10.28996/1680-4422-2017-1-22-206.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wittens C., Davies A.H., Bækgaard N., Broholm R., Cavezzi A., Chastanet S. et al. Editor’s Choice – Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678–737. https://doi.org/10.1016/j.ejvs.2015.02.007.</mixed-citation><mixed-citation xml:lang="en">Wittens C., Davies A.H., Bækgaard N., Broholm R., Cavezzi A., Chastanet S. et al. Editor’s Choice – Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678–737. https://doi.org/10.1016/j.ejvs.2015.02.007.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Richette P., Doherty M., Pascual E., Barskova V., Becce F., CastanedaSanabria J. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. https://doi.org/10.1136/annrheumdis-2016-209707.</mixed-citation><mixed-citation xml:lang="en">Richette P., Doherty M., Pascual E., Barskova V., Becce F., CastanedaSanabria J. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. https://doi.org/10.1136/annrheumdis-2016-209707.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Benn C.L., Dua P., Gurrell R., Loudon P., Pike A., Storer R.I. et al. Physiology of Hyperuricemia and Urate-Lowering Treatments. Front Med (Lausanne). 2018;5:160. https://doi.org/10.3389/fmed.2018.00160.</mixed-citation><mixed-citation xml:lang="en">Benn C.L., Dua P., Gurrell R., Loudon P., Pike A., Storer R.I. et al. Physiology of Hyperuricemia and Urate-Lowering Treatments. Front Med (Lausanne). 2018;5:160. https://doi.org/10.3389/fmed.2018.00160.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Meyers O. L, Monteagudo F.S. A comparison of gout in men and women. A 10-year experience. S Afr Med J. 1986;70(12):721–723. https://pubmed.ncbi.nlm.nih.gov/3787395.</mixed-citation><mixed-citation xml:lang="en">Meyers O. L, Monteagudo F.S. A comparison of gout in men and women. A 10-year experience. S Afr Med J. 1986;70(12):721–723. https://pubmed.ncbi.nlm.nih.gov/3787395.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
